U.S. markets open in 1 hour 51 minutes

Collegium Pharmaceutical, Inc. (COLL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.86-0.18 (-0.69%)
At close: 04:00PM EST
25.86 0.00 (0.00%)
After hours: 04:02PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close26.04
Bid10.35 x 1200
Ask41.37 x 800
Day's Range25.55 - 26.04
52 Week Range20.83 - 30.22
Avg. Volume300,531
Market Cap843.318M
Beta (5Y Monthly)0.90
PE Ratio (TTM)107.75
EPS (TTM)0.24
Earnings DateFeb 21, 2024 - Feb 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-4% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for COLL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Collegium Pharmaceutical, Inc.
    COLL: Raising target price to $27.00COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent

    STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision affirming the invalidity of Purdue’s ‘961 patent confirms b

  • Insider Monkey

    12 Cheap NASDAQ Stocks To Buy

    In this piece, we will take a look at the 12 cheap NASDAQ stocks to buy. To skip our overview of one of the world’s largest stock exchanges and some recent financial news, read 5 Cheap NASDAQ Stocks To Buy. Stocks markets have been taking a hammering over the past couple of years amid a […]

  • GlobeNewswire

    Collegium Announces $25 Million Accelerated Share Repurchase Program

    STOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized